Component
Hypoglycemia during an insulin-modified glucose test
Hypoglycemia during an insulin-modified glucose test. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Risk carriers had no insulin-induced hypoglycemia events with melatonin versus seven with placebo in the test.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"}
- experimental_model
- Randomized double-blind placebo-controlled crossover physiology trial
- exposure
- 5 mg oral melatonin; five-day laboratory protocol
- limitations
- Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations.
- nutrient_topic
- Melatonin research collection; topical membership is not evidence of a direct dietary effect. · Melatonin
- organism
- 21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers
- plain_language
- This experimental observation is not evidence to use melatonin as a hypoglycemia treatment.
- primary_references
- [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
- tissue_or_cell_type
- Insulin-modified IV glucose test and beta-cell modeling
Melatonin: synthesis, receptors, circadian timing and nutrient interactions (2026-09-17) · lines 1228–1239
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled crossover physiology trial · source_derived_draft · unverified_draft
### melatonin-2026-hypoglycemia Risk carriers had no insulin-induced hypoglycemia events with melatonin versus seven with placebo in the test. Condition category: normal nutrient_topic: Melatonin research collection; topical membership is not evidence of a direct dietary effect. plain_language: This experimental observation is not evidence to use melatonin as a hypoglycemia treatment. organism: 21 healthy European-ancestry participants: 10 risk carriers, 11 noncarriers tissue_or_cell_type: Insulin-modified IV glucose test and beta-cell modeling experimental_model: Randomized double-blind placebo-controlled crossover physiology trial limitations: Small genotype-stratified acute study published in 2026. Stronger carrier findings are not a population-wide diabetes risk estimate or evidence about all chronic formulations. exposure: 5 mg oral melatonin; five-day laboratory protocol evidence_span: {"source_cache": "artifacts/melatonin-research/42346809.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6", "start_char": 0, "end_char": 1941, "text_sha256": "a8e4b84650338084b0a878a3b06138c9ef65502d7f9b119877434421b5131bc6"} [melatonin-p42346809] Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. (2026). https://pubmed.ncbi.nlm.nih.gov/42346809/ DOI: 10.2337/dc26-0164
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.